Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;5(Suppl 4):e001034.
doi: 10.1136/esmoopen-2020-001034.

Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours

Affiliations
Review

Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours

Emilie Le Rhun et al. ESMO Open. 2020 Nov.

Abstract

Recent years have seen a great interest in sex-specific aspects of many diseases, including cancer, in part because of the assumption that females have often not been adequately represented in early drug development and determination of safety, tolerability and efficacy in clinical trials. Brain tumours represent a highly heterogeneous group of neoplastic diseases with strong variation of incidence by age, but partly also by sex. Most gliomas are more common in men whereas meningiomas, the most common primary intracranial tumours, are more common in females. Potential sex-specific genetic risk factors and specific sex biology have been reported in a tumour-specific manner. Several small studies have indicated differences in tolerability and safety of, as well as benefit from, treatment by sex, but no conclusive data have been generated. Exploring sex-specific aspects of neuro-oncology should be studied more systematically and in more depth in order to uncover the biological reasons for known sex differences in this disease.

Keywords: female; glioma; male; meningioma; sex.

PubMed Disclaimer

Conflict of interest statement

Competing interests: ELR has received honoraria for lectures or advisory board participation or consulting from Abbvie, Daiichi Sankyo, Tocagen. MW has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb, Celgene, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen.

References

    1. Louis DN, Perry A, Reifenberger G, et al. . The 2016 World Health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20. 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Ostrom QT, Cioffi G, Gittleman H, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–100. 10.1093/neuonc/noz150 - DOI - PMC - PubMed
    1. Mindermann T, Wilson CB. Age-Related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994;41:359–64. 10.1111/j.1365-2265.1994.tb02557.x - DOI - PubMed
    1. Gramatzki D, Dehler S, Rushing EJ, et al. . Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer 2016;122:2206–15. 10.1002/cncr.30023 - DOI - PubMed
    1. Surawicz TS, McCarthy BJ, Kupelian V, et al. . Descriptive epidemiology of primary brain and CNS tumors: results from the central brain tumor registry of the United States, 1990-1994. Neuro Oncol 1999;1:14–25. 10.1093/neuonc/1.1.14 - DOI - PMC - PubMed